Genetic Causes of Monoamine Deficiency

By SWA

Monoamine deficiency refers to a reduction in the levels or function of monoamine neurotransmitters—such as serotonin, dopamine, and norepinephrine—in the brain. These neurotransmitters play a critical role in regulating mood, motivation, attention, and emotional well-being. When their levels are disrupted, it can lead to various neurological and psychiatric disorders, including depression, anxiety, ADHD, and Parkinson’s disease.

While diet, stress, inflammation, and neurodegenerative diseases can contribute to monoamine deficiency, genetic factors play a crucial role in determining an individual's baseline neurotransmitter levels and function. Genetic variations or mutations in specific genes can impair the production, transport, breakdown, or receptor function of monoamines, leading to imbalances that contribute to mental health and neurological disorders.

Key Genes Involved in Monoamine Deficiency

1. SLC6A4 (Serotonin Transporter Gene, 5-HTT)

  • Function: Encodes the serotonin transporter (SERT), responsible for clearing serotonin from the synaptic cleft.
  • Key Variation: The 5-HTTLPR polymorphism has two main alleles:
    • Short (S) allele → Reduced serotonin reuptake efficiency → Increased risk of depression and anxiety.
    • Long (L) allele → Normal serotonin reuptake → More resilience to stress-related mood disorders.

2. TPH1 & TPH2 (Tryptophan Hydroxylase Genes)

  • Function: Encode enzymes involved in the synthesis of serotonin from tryptophan.
  • Key Variations:
    • TPH2 mutations → Reduced serotonin production → Linked to major depressive disorder (MDD), bipolar disorder, and anxiety disorders.
    • TPH1 polymorphisms may also affect serotonin levels but are primarily associated with peripheral serotonin metabolism.

3. COMT (Catechol-O-Methyltransferase Gene)

  • Function: Encodes the COMT enzyme, which breaks down dopamine, norepinephrine, and epinephrine.
  • Key Variation: The Val158Met polymorphism affects dopamine metabolism:
    • Val/Val → Faster dopamine breakdown → Lower dopamine levels → Linked to ADHD, cognitive deficits, and impulsivity.
    • Met/Met → Slower dopamine breakdown → Higher dopamine levels → Associated with increased anxiety and schizophrenia risk.

4. MAOA & MAOB (Monoamine Oxidase Genes)

  • Function: Encode enzymes that break down serotonin, dopamine, and norepinephrine.
  • Key Variations:
    • MAOA-L (low-activity variant) → Reduced monoamine breakdown → Linked to aggression, impulsivity, and depression.
    • MAOA-H (high-activity variant) → Increased monoamine breakdown → May contribute to lower serotonin levels and mood disorders.

5. SLC6A3 (Dopamine Transporter Gene, DAT1)

  • Function: Encodes the dopamine transporter (DAT), which removes dopamine from the synapse.
  • Key Variation: The 10-repeat allele is associated with increased dopamine reuptake, leading to:
    • Lower dopamine levels in key brain regions.
    • Higher risk of ADHD and reduced reward sensitivity.

6. DRD2 & DRD4 (Dopamine Receptor Genes)

  • Function: Encode dopamine receptors, which are essential for dopamine signaling in the brain.
  • Key Variations:
    • DRD2 Taq1A polymorphism → Reduced dopamine receptor density → Linked to depression, addiction, and motivation deficits.
    • DRD4 7-repeat allele → Altered dopamine signaling → Associated with ADHD, impulsivity, and novelty-seeking behaviors.

Genetic Testing & Personalized Medicine

Advancements in genetic testing and pharmacogenomics allow individuals to assess their monoamine-related gene variants and predict how they might respond to medications, including:

  • Selective serotonin reuptake inhibitors (SSRIs) for depression and anxiety.
  • Stimulants (e.g., methylphenidate, amphetamines) for ADHD.
  • Dopamine agonists for Parkinson’s disease.

Understanding genetic predispositions can help tailor treatment strategies, optimize medication choices, and improve outcomes for individuals with monoamine-related disorders.

Conclusion

Monoamine deficiency has a strong genetic basis, with variations in key genes affecting neurotransmitter production, transport, breakdown, and receptor function. These genetic factors contribute to mental health disorders like depression, anxiety, and ADHD, as well as neurodegenerative diseases like Parkinson’s. Identifying these genetic markers through genetic testing and personalized medicine may lead to more effective, individualized treatments, helping people manage their mental health and neurological conditions more efficiently.

Reference: Depression: The case for a monoamine deficiency.
https://psycnet.apa.org/record/2000-03492-002

© 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9

Comments

Post a Comment

Popular posts from this blog

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By SWA
Image
Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially presenting as petechiae, diagnosed by a rheumatologist. However, following the second dose, symptoms rapidly escalated, resulting in intense burning pain and thinning of the skin. The skin on the legs and thighs became paper-thin and could tear with the slightest touch, with the affected area e...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By SWA
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By SWA
Image
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
Read more